8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Genomic testing is often limited by the exhaustible nature of human tissue and blood samples. Here we describe biotinylated amplicon sequencing (BAmSeq), a method that allows for the creation of PCR amplicon based next-generation sequencing (NGS) libraries while retaining the original source DNA.

          Design and methods

          Biotinylated primers for different loci were designed to create NGS libraries using human genomic DNA from cell lines, plasma, and formalin-fixed paraffin embedded (FFPE) tissues using the BAmSeq protocol. DNA from the original template used for each BAmSeq library was recovered after separation with streptavidin magnetic beads. The recovered DNA was then used for end-point, quantitative and droplet digital PCR (ddPCR) as well as NGS using a cancer gene panel.

          Results

          Recovered DNA was analyzed and compared to the original DNA after one or two rounds of BAmSeq. Recovered DNA revealed comparable genomic distributions and mutational allelic frequencies when compared to original source DNA. Sufficient quantities of recovered DNA after BAmSeq were obtained, allowing for additional downstream applications.

          Conclusions

          We demonstrate that BAmSeq allows original DNA template to be recovered with comparable quality and quantity to the source DNA. This recovered DNA is suitable for many downstream applications and may prevent sample exhaustion, especially when DNA quantity or source material is limiting.

          Highlights

          • Modification of targeted panel sequencing allows for recovery of original DNA template.

          • Protocol provides value in the setting of scarce DNA template.

          • Recovered DNA is suitable for NGS, ddPCR and qPCR.

          • Recovered DNA shows no loss of genomic regions.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Detection and quantification of rare mutations with massively parallel sequencing.

          The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Although massively parallel sequencing instruments are in principle well suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. The keys to this approach, called the Safe-Sequencing System ("Safe-SeqS"), are (i) assignment of a unique identifier (UID) to each template molecule, (ii) amplification of each uniquely tagged template molecule to create UID families, and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are considered mutant ("supermutants") only if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

            Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Detecting ultralow-frequency mutations by Duplex Sequencing.

              Duplex Sequencing (DS) is a next-generation sequencing methodology capable of detecting a single mutation among >1 × 10(7) wild-type nucleotides, thereby enabling the study of heterogeneous populations and very-low-frequency genetic alterations. DS can be applied to any double-stranded DNA sample, but it is ideal for small genomic regions of <1 Mb in size. The method relies on the ligation of sequencing adapters harboring random yet complementary double-stranded nucleotide sequences to the sample DNA of interest. Individually labeled strands are then PCR-amplified, creating sequence 'families' that share a common tag sequence derived from the two original complementary strands. Mutations are scored only if the variant is present in the PCR families arising from both of the two DNA strands. Here we provide a detailed protocol for efficient DS adapter synthesis, library preparation and target enrichment, as well as an overview of the data analysis workflow. The protocol typically takes 1-3 d.
                Bookmark

                Author and article information

                Contributors
                Journal
                Pract Lab Med
                Pract Lab Med
                Practical Laboratory Medicine
                Elsevier
                2352-5517
                09 August 2018
                November 2018
                09 August 2018
                : 12
                : e00108
                Affiliations
                [a ]The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
                [b ]The Sidney Kimmel Comprehensive Cancer Center, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
                [c ]Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
                [d ]The Whiting School of Engineering, Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States
                Author notes
                [* ]Correspondence to: 1650 Orleans Street, Room 151, Baltimore, MD 21287, United States. bpark2@ 123456jhmi.edu
                Article
                S2352-5517(18)30050-7 e00108
                10.1016/j.plabm.2018.e00108
                6104457
                30140723
                bccf60a6-0743-4c34-8cd0-50c3a1b90b8f
                © 2018 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 22 April 2018
                : 6 July 2018
                : 8 August 2018
                Categories
                Article

                bamseq, biotinylated amplicon sequencing,ngs, next generation sequencing,ffpe, formalin-fixed paraffin embedded,cfdna, circulating cell-free dna,gdna, genomic dna,pdna, plasma dna,qpcr, quantitative polymerase chain reaction,ddpcr, droplet digital pcr,next generation sequencing,plasma dna,droplet digital pcr (ddpcr),targeted amplicon sequencing

                Comments

                Comment on this article